BR112018067969A2 - uso de células estaminais de polpa dentária que expressam marcadores neuronais mesenquimais e composições das mesmas para tratar doença neurológica - Google Patents

uso de células estaminais de polpa dentária que expressam marcadores neuronais mesenquimais e composições das mesmas para tratar doença neurológica

Info

Publication number
BR112018067969A2
BR112018067969A2 BR112018067969A BR112018067969A BR112018067969A2 BR 112018067969 A2 BR112018067969 A2 BR 112018067969A2 BR 112018067969 A BR112018067969 A BR 112018067969A BR 112018067969 A BR112018067969 A BR 112018067969A BR 112018067969 A2 BR112018067969 A2 BR 112018067969A2
Authority
BR
Brazil
Prior art keywords
stem cells
dental pulp
neurological disease
compositions
hydpss
Prior art date
Application number
BR112018067969A
Other languages
English (en)
Inventor
Valverde Wenceslau Cristiane
Kerkis Irina
Original Assignee
Avita Int Ltd
Fund Butantan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/065,259 external-priority patent/US11207352B2/en
Application filed by Avita Int Ltd, Fund Butantan filed Critical Avita Int Ltd
Publication of BR112018067969A2 publication Critical patent/BR112018067969A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0664—Dental pulp stem cells, Dental follicle stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)

Abstract

a invenção fornece composições farmacêuticas compreendendo células estaminais de polpa dentária imaturas humanas (hidpscs), em que as hidpscs expressam cd44 e cd13. a invenção também fornece métodos de tratamento de uma doença ou condição neurológica compreendendo administrar sistemicamente a um indivíduo uma composição farmacêutica compreendendo hidpscs, em que as hidpscs expressam cd44 e cd13. por exemplo, para o tratamento de doenças ou condições neurológicas, incluindo o suporte ao mecanismo de neuroproteção em indivíduos diagnosticados com hd inicial ou a reparação de neurônios da perdidos em indivíduos diagnosticados com dp.
BR112018067969A 2016-03-09 2017-03-09 uso de células estaminais de polpa dentária que expressam marcadores neuronais mesenquimais e composições das mesmas para tratar doença neurológica BR112018067969A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/065,259 US11207352B2 (en) 2013-03-15 2016-03-09 Compositions comprising stem cells expressing mesenchymal and neuronal markers and uses thereof to treat neurological disease
PCT/IB2017/051404 WO2017153956A1 (en) 2016-03-09 2017-03-09 Uses of dental pulp stem cells expressing mesenchymal and neuronal markers and compositions thereof to treat neurological disease

Publications (1)

Publication Number Publication Date
BR112018067969A2 true BR112018067969A2 (pt) 2019-01-15

Family

ID=58387859

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112018067971A BR112018067971A2 (pt) 2016-03-09 2017-03-09 células estaminais que expressam marcadores mesenquimais e neuronais, composições das mesmas, e métodos de preparação das mesmas
BR112018067969A BR112018067969A2 (pt) 2016-03-09 2017-03-09 uso de células estaminais de polpa dentária que expressam marcadores neuronais mesenquimais e composições das mesmas para tratar doença neurológica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112018067971A BR112018067971A2 (pt) 2016-03-09 2017-03-09 células estaminais que expressam marcadores mesenquimais e neuronais, composições das mesmas, e métodos de preparação das mesmas

Country Status (9)

Country Link
EP (2) EP3426267B1 (pt)
JP (2) JP6997716B2 (pt)
KR (2) KR102497999B1 (pt)
CN (2) CN109219441B (pt)
BR (2) BR112018067971A2 (pt)
CA (2) CA3055398A1 (pt)
IL (2) IL261623B2 (pt)
RU (2) RU2742828C2 (pt)
WO (2) WO2017153956A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110799200A (zh) * 2017-05-26 2020-02-14 仲恩生医科技股份有限公司 用于多麸酰氨酸(polyq)疾病的治疗
WO2020027163A1 (ja) * 2018-07-31 2020-02-06 Ｊｃｒファーマ株式会社 歯髄由来細胞の製造方法
CN110179827A (zh) * 2019-06-27 2019-08-30 北京三有利和泽生物科技有限公司 牙源性间充质干细胞的应用
CN110314172A (zh) * 2019-07-17 2019-10-11 中国医科大学附属第一医院 一种用于治疗脊髓损伤的细胞制剂及其制备方法
US20230172992A1 (en) * 2020-03-31 2023-06-08 Cell Exosome Therapeutics Inc. Method for producing proliferating cells, method for producing cell product, mesenchymal stem cell population and method for producing same, culture supernatant of stem cells and method for producing same, and therapeutic agent
CN111973631A (zh) * 2020-08-21 2020-11-24 卡替(上海)生物技术有限公司 牙髓间充质干细胞在制备阿尔茨海默病治疗药物中的用途
CN115192609A (zh) * 2022-05-10 2022-10-18 湖南中南大学湘雅口腔医院 间充质干细胞在制备治疗抑郁症的药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101243178A (zh) 2005-06-16 2008-08-13 特拉维夫大学拉莫特有限公司 用于治疗cns疾病的分离细胞和包含这种细胞的细胞群
WO2008080200A1 (en) * 2006-12-29 2008-07-10 Irina Kerkis Process for obtaining stem cells
EP2137300B1 (en) 2007-04-26 2011-10-26 Ramot at Tel-Aviv University Ltd. Pluripotent autologous stem cells from oral or gastrointestinal mucosa
RU2347579C1 (ru) * 2007-07-03 2009-02-27 Общество с ограниченной ответственностью "Медицинские технологии" Способ получения клеточной культуры для лечения сосудистых и демиелинизирующих заболеваний нервной системы и клеточная культура, полученная этим способом (варианты)
US20110002895A1 (en) * 2007-12-05 2011-01-06 Minoru Ueda Composition for autotransplantation or allotransplantation using dental pulp stem cell, and use of the composition
CN101970022A (zh) * 2008-03-12 2011-02-09 财团法人日本健康科学振兴财团 根管填充材料以及牙组织再生方法
EP3514229A1 (en) 2008-05-28 2019-07-24 Ramot at Tel-Aviv University Ltd. Mesenchymal stem cells for the treatment of cns diseases
ITRM20080342A1 (it) * 2008-06-26 2009-12-27 Univ Degli Studi Udine Cellule di polpa dentale midollo-simili, metodi per isolamento ed uso.
WO2011078011A1 (ja) * 2009-12-21 2011-06-30 学校法人 総持学園 鶴見大学 歯髄細胞の培養及び保存用抜去歯の移送方法
EP2680864B1 (en) 2011-03-03 2019-05-08 Ramot at Tel-Aviv University Ltd. Genetically modified muscle cells which express neurotrophic factors
US9717761B2 (en) 2011-11-21 2017-08-01 Ramot At Tel-Aviv University Ltd. Stem cell-derived neural cells for cell therapy in neurological disorders
EP2633870B1 (en) * 2012-02-29 2018-08-01 Technische Universität Berlin Method of preparing an artificial tooth primordium in vitro and artificial tooth primordium derived therefrom
US9790468B2 (en) * 2013-03-15 2017-10-17 Avita Iinternational Ltd. Multifunctional immature dental pulp stem cells and therapeutic applications

Also Published As

Publication number Publication date
IL261623B1 (en) 2023-11-01
JP6997716B2 (ja) 2022-02-04
CA3055399A1 (en) 2017-09-14
CN109219441A (zh) 2019-01-15
IL261623A (en) 2018-10-31
IL261622B1 (en) 2023-05-01
IL261622A (en) 2018-10-31
CN109312303A (zh) 2019-02-05
JP7008031B2 (ja) 2022-02-10
BR112018067971A2 (pt) 2019-01-15
RU2018134710A3 (pt) 2020-06-25
RU2018134710A (ru) 2020-04-09
RU2741839C2 (ru) 2021-01-29
KR20190003489A (ko) 2019-01-09
IL261622B2 (en) 2023-09-01
RU2018134615A3 (pt) 2020-07-28
KR20180137488A (ko) 2018-12-27
RU2018134615A (ru) 2020-04-10
KR102363146B1 (ko) 2022-02-14
EP3426267A1 (en) 2019-01-16
WO2017153957A9 (en) 2017-11-02
EP3426770A1 (en) 2019-01-16
EP3426267B1 (en) 2023-01-11
JP2019510758A (ja) 2019-04-18
JP2019507772A (ja) 2019-03-22
KR102497999B1 (ko) 2023-02-08
WO2017153957A1 (en) 2017-09-14
RU2742828C2 (ru) 2021-02-11
CN109219441B (zh) 2022-06-10
CA3055398A1 (en) 2017-09-14
CN109312303B (zh) 2024-03-26
IL261623B2 (en) 2024-03-01
WO2017153956A1 (en) 2017-09-14

Similar Documents

Publication Publication Date Title
BR112018067969A2 (pt) uso de células estaminais de polpa dentária que expressam marcadores neuronais mesenquimais e composições das mesmas para tratar doença neurológica
BR112022010349A2 (pt) Compostos bifuncionais para degradar btk por meio de via da ubiquitina-proteossoma
WO2018115097A9 (en) Ophthalmic composition for treatment of dry eye disease
BR112017009807A2 (pt) métodos e formulações para tratamento de doenças oculares vasculares
ES2422739T3 (es) Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB
BR112018073683A2 (pt) polinucleotídeos codificadores de relaxina
BR112018068066A2 (pt) compostos bicíclicos para diagnóstico e terapia
BR112014027155A2 (pt) composições de celúlas t deficientes do re-ceptor de células t
BR112012004806B8 (pt) composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso
BR112016025312A2 (pt) variantes de anticorpo, anticorpo anti-fator d, formulação farmacêutica, dispositivo de distribuição, utilização da formulação e de uma composição, composição e método de tratamento de uma desordem
BR112017017448A2 (pt) métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho
DOP2011000045A (es) Anticuerpos monoclonales contra el inhibidor de la via del factor tisular (tfpi)
UY31816A (es) Agente para el tratamiento y/o prevención de una enfemedad autoinmune y para la formación de células t reguladoras
CL2017002825A1 (es) Formulaciones de tpp1 y métodos para tratar la enfermedad de cln2
MX2018004170A (es) Biomarcadores relacionados con enfermedades mediadas por interleucina-33 (il-33) y usos de los mismos.
EA201792487A1 (ru) Композиции гидроксипропил-бета-циклодекстринов и способы
BR112018013227A2 (pt) ?composições farmacêuticas ou kit para o uso, métodos para tratar câncer em um mamífero e uso de uma composição?
BR112018076639A2 (pt) quimioterapias de combinação
AR101236A1 (es) Composiciones para el cuidado oral
BR112015022650A8 (pt) inibidores de quinase induzível por sal macrocíclico.
BR112015019873A2 (pt) inibidores macrocíclicos da lrrk2 cinase
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
CL2019000914A1 (es) Composiciones de combinaciones que comprenden agonistas de fxr para tratar o prevenir una enfermedad o un trastorno fibrótico o cirrótico.
BR112017013674A2 (pt) métodos e composições para tratamento de doenças cerebrais.
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]